40928-15-2

Basic information

• Product Name: 2-amino-N-methoxy-benzamide
• Synonyms: 2-amino-N-methoxy-benzamide
• CAS NO: 40928-15-2
• Molecular Weight: 166.18
• Mol File: 40928-15-2.mol
• Article Data: 9

Chemical Properties

• CAS DataBase Reference: 2-amino-N-methoxy-benzamide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-amino-N-methoxy-benzamide(40928-15-2)
• EPA Substance Registry System: 2-amino-N-methoxy-benzamide(40928-15-2)

Safety Data

• Hazardous Substances Data: 40928-15-2(Hazardous Substances Data)

Upstream product

• 118-48-9 isatoic anhydride 
• 593-56-6 N-methoxylamine hydrochloride 
• 5344-90-1 2-Aminobenzyl alcohol 
• 67-62-9 O-Methylhydroxylamin 

Downstream Products

• 40928-18-5 2-amino-5-bromo-N-methoxybenzamide 
• 1184931-57-4 2-(5-bromo-2-chloro-pyridin-4-ylamino)-N-methoxy-benzamide 
• 1453199-51-3 2-(2-(5-amino-2-methoxyphenylamino)-5-chloropyrimidin-4-ylamino)-N-methoxybenzamide 
• 1453199-52-4 2-(2-(5-acrylamido-2-methoxyphenylamino)-5-chloropyrimidin-4-ylamino)-N-methoxybenzamide 
• 1453199-60-4 2-(5-chloro-2-(2-methoxy-5-(vinylsulfonamido)phenylamino)pyrimidin-4-ylamino)-Nmethoxybenzamide 
• 1453199-49-9 2-(5-chloro-2-(2-methoxy-5-nitrophenylamino)pyrimidin-4-ylamino)-N-methoxybenzamide 
• 1453199-48-8 2-((2,5-dichloropyrimidin-4-yl)amino)-N-methoxybenzamide 
• 1264037-81-1 2-(2-(trifluoromethyl)phenyl)quinazolin-4(3H)-one 
• 18818-41-2 2-(4-methylphenyl)-4(3H)-quinazolinone 
• 1152-07-4 2-(4-methoxyphenyl)-3H-quinazolin-4-one 
• 89860-51-5 2-(4-hydroxyphenyl)-4(3H)-quinazolinone 
• 1613113-57-7 2-(2,6-dichlorophenyl)quinazolin-4(3H)-one 
• 132982-03-7 2-(3¹,4¹-dimethoxyphenyl)quinazol-4-one 
• 1642134-19-7 (E)-2-(1-phenylprop-1-en-2-yl)quinazolin-4(3H)-one 

Relevant articles and documents

SUBSTITUTED PYRIMIDINES, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC METHODS THEREOF

The invention provide novel pyrimidine derivatives and analogs having inhibitory activities towards certain tyrosine kinases, e.g., Bruton's tyrosine kinase (Btk) and/or Focal adhesion kinase (FAK), extracellular signal-regulated kinase (ERK), pharmaceutical compositions thereof, and methods of treatment, reduction or prevention of certain diseases or conditions mediated by such by tyrosine kinases, e.g., cancers, tumors, fibrosis, inflammatory diseases, autoimmune diseases, diabetes, or immunologically mediated diseases.

Focal adhesion kinase inhibitor and use

The invention belongs to the field of medicines, relates to a focal adhesion kinase inhibitor and use, in particular relates to a novel focal adhesion kinase inhibitor compound, or stereoisomers, geometric isomers, tautomers, oxynitrides, hydrates, solvates, metabolites, pharmaceutically acceptable salts or prodrugs thereof, further relates to the use of the compound and pharmaceutical compositions as medicines, in particular the use of the compound and pharmaceutical compositions in manufacture of medicines for treatment or prevention of cancer, pulmonary hypertension, and pathological angiogenesis-related diseases.

Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR)

A novel series of small-molecule inhibitors has been developed to target the double mutant form of the epidermal growth factor receptor (EGFR) tyrosine kinase, which is resistant to treatment with gefitinib and erlotinib. Our reported compounds also show selectivity over wild-type EGFR. Guided by molecular modeling, this series was evolved to target a cysteine residue in the ATP binding site via covalent bond formation and demonstrates high levels of activity in cellular models of the double mutant form of EGFR. In addition, these compounds show significant activity against the activating mutations, which gefitinib and erlotinib target and inhibition of which gives rise to their observed clinical efficacy. A glutathione (GSH)-based assay was used to measure thiol reactivity toward the electrophilic functionality of the inhibitor series, enabling both the identification of a suitable reactivity window for their potency and the development of a reactivity quantitative structure-property relationship (QSPR) to support design.